AlphAIAlphAI — Financial news for AI agents
investing.com$ZBH

Jefferies raises Zimmer Biomet stock price target on guidance lift

Jefferies raised its price target on Zimmer Biomet (ZBH) to $120 from $105, maintaining a Hold rating. The company reported Q3 2026 sales of $2.06B, up 3.7% YoY, and EPS of $1.90, flat YoY. Zimmer Biomet lifted its fiscal 2026 organic growth guidance to 3%-3.5% and EPS guidance to $8.50-$8.60. The stock trades at $110.64, near its 52-week high.

Original reporting
investing.com
Published Nov 4, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The analyst's higher target and guidance could attract new buying interest, especially from investors focused on medical device growth.

02

Market read

Analyst upgrade with new price target and guidance provides a fresh catalyst for ZBH, potentially influencing its short‑term price action.

03

What to watch

Potential supply‑chain constraints could temper growth despite higher guidance.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Jefferies' upgrade follows Zimmer Biomet's Q3 2026 earnings beat and raised FY guidance.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Jefferies raised its price target on Zimmer Biomet to $120 and lifted FY2026 guidance after the company's Q3 earnings beat.

Expected impact

likely upward pressure as investors price in the higher target and guidance

Evidence & confidence

The new target is 9% above the current price and guidance was raised, indicating improved outlook.

Market effects

Sector

May boost sentiment for the broader orthopedic devices sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited to markets with exposure to Zimmer Biomet.

Counterpoint

What could challenge this read

The upgrade may be premature if knee segment weakness persists.

Key entities

  • company
    Zimmer Biomet Holdings Inc.

    Medical device manufacturer that reported Q3 earnings and received an analyst upgrade.

  • analyst
    Jefferies

    Equity research firm that raised the price target and guidance.

Read at source← All news

StoryZimmer Biomet reports Q3 2026 results and lifts full‑year guidance

Also covered by

5 outlets

Related articles

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.

finance.yahoo.com
$ZBHHighAI 8/10

Zimmer raises sales forecast despite slower knee business

Zimmer Biomet reported Q3 sales of $2.06B, up 3.1% YoY, with knee sales down 3.1% but hip sales up 6%. The company raised its 2026 revenue growth forecast to 4.4-4.9%. CEO Ivan Tornos attributed knee sales decline to commercial execution and market competition, not a broader slowdown, according to the company. Analysts, however, suggest market-related weakness. Zimmer plans to file an FDA application for a new surgical robot, acquired via Monogram Technologies, expecting a 2027 launch.

finance.yahoo.com
$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.com
$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

rttnews.com